Dashboard
Manage Tickers

ADCT


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-adc-therapeutics-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on ADC ...
08/08/2024 11:29:20

HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $8 price target.

rbc-capital-reiterates-outperform-on-adc-therapeutics-maintains-8-price-target
RBC Capital Reiterates Outperform on ADC T...
08/07/2024 15:32:00

RBC Capital analyst Gregory Renza reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and maintains $8 price target.

adc-therapeutics-cash-and-cash-equivalents-were-3001m-as-of-june-30-extending-the-expected-cash-runway-into-mid-2026
ADC Therapeutics' Cash And Cash Equivalent...
08/06/2024 11:37:10

adc-therapeutics-q2-2024-adj-eps-025-beats-046-estimate-sales-17410m-miss-18798m-estimate
ADC Therapeutics Q2 2024 Adj. EPS $(0.25) ...
08/06/2024 11:32:46

intapp-servicenow-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
Intapp, ServiceNow And Other Big Stocks Mo...
07/08/2024 12:22:50

adc-therapeutics-is-set-to-join-the-russell-2000-index-and-the-broad-market-russell-3000-index-after-the-2024-russell-us-indexes-annual-reconstitution-effective-at-the-open-of-us-equity-markets-on-monday-july-1-2024
ADC Therapeutics Is Set To Join The Russel...
06/27/2024 11:22:24

cantor-fitzgerald-initiates-coverage-on-adc-therapeutics-with-overweight-rating
Cantor Fitzgerald Initiates Coverage On AD...
05/30/2024 12:55:50

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on ADC Therapeutics (NYSE:ADCT) with a Overweight rating.

hc-wainwright--co-maintains-buy-on-adc-therapeutics-lowers-price-target-to-8
HC Wainwright & Co. Maintains Buy on ADC T...
05/07/2024 10:29:23

HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target f...

biontech-reports-downbeat-earnings-joins-medical-properties-trust-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
BioNTech Reports Downbeat Earnings, Joins ...
05/06/2024 11:32:06

adc-therapeutics-currently-expects-its-cash-runway-to-extend-into-q4-of-2025
ADC Therapeutics Currently Expects Its Cas...
05/06/2024 10:14:29

adc-therapeutics-q1-2024-adj-eps-038-beats-056-estimate-sales-18053m-miss-18102m-estimate
ADC Therapeutics Q1 2024 Adj EPS $(0.38) B...
05/06/2024 10:12:27

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.56...

adc-therapeutics-announces-initial-data-from-investigator-initiated-phase-2-clinical-trial-of-zynlonta-in-patients-with-relapsedrefractory-marginal-zone-lymphoma
ADC Therapeutics Announces Initial Data fr...
05/06/2024 10:04:38

ADC Therapeutics SA (NYSE:ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluat...

medifast-reports-mixed-results-joins-coursera-chegg-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session
Medifast Reports Mixed Results, Joins Cour...
04/30/2024 10:07:45

hc-wainwright--co-reiterates-buy-on-adc-therapeutics-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on ADC ...
04/15/2024 11:51:57

HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $9 price target.

guggenheim-reiterates-buy-on-adc-therapeutics
Guggenheim Reiterates Buy on ADC Therapeutics
04/05/2024 13:55:28

Guggenheim analyst Michael Schmidt reiterates ADC Therapeutics (NYSE:ADCT) with a Buy.

adc-therapeutics-announces-updates-on-lotis-7-clinical-trial-evaluating-zynlonta-in-combination-with-glofitamab-or-mosunetuzumab-in-patients-with-relapsedrefractory-b-cell-non-hodgkin-lymphoma
ADC Therapeutics Announces Updates on LOTI...
04/04/2024 11:05:59

ADC Therapeutics SA (NYSE:ADCT) today announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical tr...

guggenheim-initiates-coverage-on-adc-therapeutics-with-buy-rating-announces-price-target-of-11
Guggenheim Initiates Coverage On ADC Thera...
03/28/2024 10:45:45

Guggenheim analyst Michael Schmidt initiates coverage on ADC Therapeutics (NYSE:ADCT) with a Buy rating and announces Price ...

rbc-capital-reiterates-outperform-on-adc-therapeutics-maintains-8-price-target
RBC Capital Reiterates Outperform on ADC T...
03/14/2024 15:12:27

RBC Capital analyst Gregory Renza reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and maintains $8 price target.

dollar-tree-reports-weak-earnings-joins-tesla-arcos-dorados-and-other-big-stocks-moving-lower-on-wednesday
Dollar Tree Reports Weak Earnings, Joins T...
03/13/2024 14:22:00

U.S. stocks were mixed, with the Dow Jones index surging more than 100 points on Wednesday.

adc-therapeutics-2023-cash-and-cash-equivalents-of-2786m-is-expected-to-provide-cash-runway-into-fourth-quarter-of-2025
ADC Therapeutics' 2023 Cash And Cash Equiv...
03/13/2024 11:04:07

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION